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Forced expiratory volume 1;
Airway hyper-responsivenessAbstract Background: Chronic obstructive pulmonary disease (COPD) is defined as a disease
characterised by partially reversible and progressive airflow limitation associated with an abnormal
inflammatory response of the lung with systemic manifestation. COPD is influenced by both envi-
ronmental and genetic factors. ADAM33 (a disintegrin and metalloproteinase 33) has been one of
the most exciting candidate genes for asthma and it was first associated with the disease in Cau-
casian populations. Recently, ADAM33 was shown to be associated with excessive decline of lung
function and COPD. The aim of the study was to investigate the association of ADAM33 – S1 and
S2 polymorphisms with COPD.
Subjects and methods: A total of 150 COPD patients attending the Department of Pulmonary
Medicine, Government Chest Hospital, Erragadda, Hyderabad, India and 200 healthy control sub-
jects were considered for the present study. A standard PCR–RFLP method was carried out for
genotyping of ADAM33 S1-A/G and S2-C/G polymorphisms in all the participants.
Results: Genotypic distribution of the control and patient groups was compared with values pre-
dicted by the Hardy–Weinberg equilibrium, odds ratios (OR) and their respective 95% confidence
intervals were used to measure the strength of association between ADAM33 S1 (A/G) and S2
(C/G) gene polymorphisms and COPD. The genotypic frequencies of ADAM33 gene S1 (A/G)
polymorphism were found to be AA/AG/GG – 36%, 56%, 8% in controls and 5.33%, 10.66%,
84% in COPD cases, respectively. Genotypic frequencies for S2 (C/G) polymorphism were found
to be CC/CG/GG – 14.47%, 78.20%, 5.92% in controls and 4%, 8% and 88% in COPD cases,ana 500
318 K. Vijaya Laxmi et al.respectively. There is a significant difference in distribution of genotypes and alleles of ADAM33 S1
and S2 gene polymorphisms between the two groups.
Conclusion: The present study suggests that the ADAM33 S1 and S2 gene promoter polymor-
phisms can be the major genetic predisposing factors in the aetiology of COPD.
 2015 Production and hosting by Elsevier B.V. on behalf of Ain Shams University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Chronic obstructive pulmonary disease (COPD) is defined as a
disease characterised by partially reversible and progressive
airflow limitation that is usually associated with an abnormal
inflammatory response of the lung with systemic manifestation
[1,2]. Most of the patients with COPD show airway hyper-
responsiveness (AHR), an exaggerated airway response to
non-specific stimuli resulting in airway obstruction. The sever-
ity of AHR is positively correlated with inflammation in lung
tissue and increased number of CD8 cells in bronchial epithe-
lium of COPD lung [3]. COPD ranks 3rd as a global cause of
death and shows a worldwide increase in both morbidity and
mortality. It becomes the second leading cause of death
worldwide by 2030 (WHO). The overall prevalence of
COPD is 4.36%. The prevalence amongst males and females
was 5.32% and 3.41%, respectively. The prevalence was found
to be increasing with an increase in age. There is a wide vari-
ation in the incidence of COPD across the various registries
in India.
Pathophysiology of COPD is a multifactorial process with
a complex inflammatory cell profile including eosinophils,
monocytes, neutrophils and lymphocytes. Along with the
inflammatory profile, increased levels of cytokines such as
IL-6, IL-8 [4], TNF-a and VEGF in stable COPD patients
are seen suggesting their key role in the pathogenesis of COPD
[5]. In contrast to asthma, the inflammatory mediators
involved in COPD are now apparent that many lipid media-
tors, inflammatory peptides, reactive oxygen and nitrogen spe-
cies (ROS), chemokines, cytokines and growth factors are
involved in orchestrating the complex inflammatory process
that results in small airway fibrosis and alveolar destruction
[6]. It is well documented that environmental and genetic deter-
minants and their interaction play a vital role in the develop-
ment of COPD [7]. Amongst various environmental factors,
long term tobacco smoke is the significant one. However, all
the smokers may not suffer from COPD, denoting that some
genetic factors are contributing in the etiopathogenesis of
COPD. The importance of proteases in extracellular matrix
(ECM) and their imbalance in the genesis of pulmonary
emphysema is generally accepted. In particular, MMPs mani-
fest along with inflammatory cytokines in COPD and receive
relatively little attention. Genomic approaches have investi-
gated multiple candidate genes and SNPs, with inconsistent
results [8]. Thus, genetic factors appear to predispose some
individuals with tobacco exposure for development of this res-
piratory disease. Research on the genetic basis for COPD is
therefore still required.
Matrix metalloproteinases (MMPs) are Zn+2 dependent
endopeptidases secreted in extracellular matrix (ECM) of
lungs. Most MMPs are secreted as latent pro-enzymesand need to be activated by proteolytic conversion [9]. They
generally do not act alone but interact with other types of pro-
teases and trigger all the other cellular components. The obser-
vations of Wright et al. (2008), demonstrated that instilled
elastases could produce emphysema in experimental animals
and the inflammatory cells and proteases play a role in COPD
[41]. It involves multiple processes including abnormal inflam-
mation, protease–antiprotease imbalance, oxidant and antiox-
idant imbalance and ECM destruction [10]. They play an
important role in the mechanism of the destruction of ECM
involving cross-linking of elastin and collagen fibrils. MMPs
and ADAMs are proteolytic enzymes that degrade the matrix
components both in normal physiological states and in
abnormal pathological processes [11].
A disintegrin and metalloproteinase 33 (ADAM33), is a
membrane anchored metalloproteinase that has a role in cell
fusion, adhesion, signalling and proteolysis. It maps on human
chromosome 20p13 encoding an open reading frame of
2442 bp consisting of 22 exons. It is expressed in lung fibrob-
lasts, heart and bronchial smooth muscle cells [12]. ADAM33
is a gene of putative interest for COPD as it was primarily
associated with susceptibility for asthma and airway hyper-
responsiveness (AHR) [13,14]. It is furthermore associated
with accelerated decline in pulmonary function in the general
and asthma population [15]. ADAM molecules are members
of type I transmembrane zymogen glycoproteins containing
an N-terminal secretion signal domain, pro-catalytic, disinte-
grin, cysteine-rich, EGF-like transmembrane domain and a
cytoplasmic (C-terminal) domain. Its complex organisation
involves eight domains that facilitate its participation in many
cellular processes. The autocatalytic removal of pro-domain
region is the activation signal for ADAM proteins, which are
presumed to have a critical role in cell adhesion, proliferation
differentiation, signalling, apoptosis and inflammatory
responses [16,17]. Overall substrate specificity and function
of ADAM33 gene are yet to be known. It is mainly involved
in tissue remodelling, a physiological process intricately related
to airway inflammation, hyper-responsiveness and airway
obstruction [18].
Garlisi and colleagues (2003) demonstrated that a2-
macroglobulin, an important member of pulmonary defence
system is cleaved by an active proteinase ADAM33 [20]. These
results suggested that ADAM33 is involved in the pathogenesis
of airway obstruction with affecting tissue remodelling, a phys-
iological process intricately related to airway inflammation
[19,20]. In a Dutch cohort, S1 and S2 polymorphisms were
examined along with other SNPs affecting the course of asthma
and have been shown to influence the decline of forced expira-
tory volume (FEV1)/forced vital capacity (FVC) ratio in lung
function [21,22]. In a German study the associations between
SNPs in ADAM33 showed an annual decline in FEV1 in
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suggested to play a role in the airway remodelling of the lungs
[24]. Genetic linkage analysis and association studies of
families with asthma across diverse ethnic back-grounds
support a relationship between ADAM33 polymorphisms
and asthma phenotypes expressed in AHR and other respira-
tory disorders [25–28]. The mouse orthologue of ADAM33
also lies in the region linked to AHR [14]. Selective expression
of the ADAM33 mRNA and its protein in adult bronchial
smooth muscle and human embryonic bronchi and surround-
ing mesenchymal cells indicate specific roles of the gene in the
observed phenotypes of AHR and airway remodelling and
there are limited studies in relation to COPD [14,29,30]. There
is selective expression of ADAM33 in lung mesenchymocytes
suggesting that alterations in its activity may underlie abnor-
malities in the function of airway smooth muscle cells and
fibroblasts linked to BHR and airway remodelling [31]. One
possible explanation is that ADAM33 may serve as a cell
surface ‘sheddase’ to release growth factors such as TGF-b
and modify cell-surface receptor expression to induce the
proliferation of airway mesenchymocytes [32]. It was observed
that individuals with a genetic predisposition for a higher
number of CD8 cells were more susceptible to a further
increase in CD8 cells, which might finally result in airflow lim-
itation [33]. Despite the above notion, negative associations
between ADAM33 polymorphisms with asthma and other
respiratory disorders have been reported from ethnically
different populations yielding inconsistent results [3,34].
Hence, the present study was aimed at understanding the role
of the transmembrane domain polymorphisms S1 and S2 of
ADAM33 in the pathophysiology of COPD.
2. Subjects and methods
A total of 150 patients (male:female 142:08) with COPD eval-
uated in the Department of Pulmonary Medicine, Government
Chest Hospital, Hyderabad, Telangana, India from October
2012 to December 2014 were enroled for study with their writ-
ten informed consent and adhered to the tenets of the Declara-
tion of Helsinki (JAMA 1997;277:925–926). The clinical
diagnosis was made according to the GOLD (The Global Ini-
tiative for Chronic Obstructive Lung Disease) guidelines of the
ATS/ERS protocol by an expert pulmonologist.
A total of 200 healthy individuals matched for age and sex
formed the control group. The subjects were included under
the study with their written informed consent. The study was
approved by the ethics committee of Institute of Genetics
and Hospital for Genetic Diseases, Hyderabad. None of the
controls had any history of COPD, bronchitis, bronchiectasis,
bronchial asthma, AHR, pneumothorax, lung cancer, allergic
broncho-pulmonary diseases and family history of COPD.
2.1. Genotyping determination of ADAM33 S1 and S2 by PCR–
RFLP assay
The genomic DNA extracted from venous blood was collected
in EDTA tubes using the standard Phenol–Chloroform
method [38]. The genotyping of ADAM33 S1 and S2 gene
polymorphisms was performed using PCR–RFLP assay using
designed forward and reverse primers [Bioserve, India],
respectively.Gene name and
fragment positionForward and reverse primersADAM33 S1 F: 50-TGTGCAGGCTGAAAGTATGC-30
R: 50-AGAGCTCTGAGGAGGGGAAC-30ADAM33 S2 F: 50-GACTGGGAGGCCACTGGA-30
R: 50-CGCAGACCATGACACCTTCCT-30The amplified PCR products of S1 polymorphism 304 bp
were digested with HinfI (Fermentas, USA) and 172 bp and
132 bp restriction digested fragments were obtained (see
Fig. 1). The amplified PCR products of S2 polymorphism
328 bp were digested with HinpI (Fermentas, USA) and
262 bp and 66 bp restriction digested fragments were obtained,
by incubating at 37 C overnight and separating the polymor-
phic fragments on 3% agarose gel indicating the gene poly-
morphisms at S1 and S2 polymorphic sites, respectively (see
Figs. 1 and 2).
2.2. Statistical analysis
Hardy–Weinberg equilibrium was tested for the gene polymor-
phisms. The allele and genotype frequencies amongst cases and
controls were compared by Chi-square test and odds ratio with
95% CI. Two-tailed p-value of <0.05 was considered signifi-
cant using Open Epi 6 software (Open Epi version 2.3.1 from
Department of Epidemiology, Rollins School of Public Health,
Emory University, Atlanta, GA 30322, USA).3. Results
The cohort is subdivided into four subgroups based on GOLD
guidelines staging mild (Stage I), moderate (Stage II), severe
(Stage III), and very severe (Stage IV) to assess the influence
of genetic variation with the disease progression. The 4 sub-
groups were comprised of 25(16.6%), 23(15.3%), 95(63.3%)
and 07(4.6%) patients, respectively. A total of 200 asymp-
tomatic age and sex matched controls were included in the pre-
sent study. The demographic characteristics such as age, sex,
addictions like smoking and alcohol consumption along with
GOLD staging were noted based on the standard proforma
[36].
The demographic and clinical data of the samples and
healthy controls under study are presented in Table 1. The
gender-wise and age distribution of patients and control sub-
jects revealed no significant difference. The proportion of
smokers in COPD patients (92%) was significantly higher than
the healthy controls. The proportion of alcoholics in COPD
patients (90%) was significantly higher than the healthy
controls.
3.1. Genotype analysis
Genotypic frequencies of ADAM33 gene S1 polymorphism
(A/G) were found to be AA/AG/GG – 5.33%, 10.66%,
84% in COPD patients while they were found to be 36%,
56%, 8% in healthy controls, respectively. Genotypic
frequencies for S2 polymorphism (C/G) were found to be
CC/CG/GG – 4%, 8% and 88% in COPD patients while they
were 14.47%, 78.20%, 5.92% in healthy controls, respectively.
Figure 1 Agarose gel electrophoresis for RFLP–PCR product of ADAM33 S1 stained with ethidium bromide. 1st column – represents
Ladder. Lanes 1, 3 and 5 represent homozygote AA genotype. Lanes 6 and 7 represent heterozygote AG genotype. Lanes 2 and 4 represent
homozygote GG genotype.
Figure 2 Agarose gel electrophoresis for RFLP–PCR product of ADAM33 S2 stained with ethidium bromide. 1st column – represents
Ladder. Lanes 1, 4 and 5 represent homozygote CC genotype. Lanes 2 and 6 represent heterozygote AG genotype. Lanes 3 and 7 represent
homozygote GG genotype.
320 K. Vijaya Laxmi et al.When homozygous genotypes (AA in S1 and CC in S2) were
taken as reference, it was found that frequencies for respective
mutant alleles GG and GG genotypes in COPD patients were
significantly associated with the disease. Genotype frequencies
of ADAM33-S1-AG and GG genotypes along with mutant G
allele were significantly associated with COPD compared to
healthy subjects [OR = 0.402(0.296–0.547), p 6 0.001*].
Genotype frequencies of ADAM33-S2-AG and GG genotypes
along with mutant G allele were significantly associated
with COPD compared to healthy subjects [OR = 0.277
(0.202–0.380), p < 0.001*]. The statistical analysis of genotypic
data and allelic frequencies revealed a significant association ofS1 (A/G) and S2 (C/G) polymorphisms in patients when
compared with controls, respectively (see Tables 1 and 2).
Moreover, in co-dominant, dominant and recessive models
in Tables 2 and 3, the results showed that ADAM33 S1-GG
and S2-GG alleles were conferring a significant increased risk
for the disease in co-dominant and dominant models. In dom-
inant model, when AA was taken as reference the frequency of
S1-AG+ GG in COPD patients was significantly higher than
that in healthy controls [OR = 0.078(0.043–0.140),
p-value < 0.001*] and when CC was taken as reference the fre-
quency of S2-CG+ GG in COPD patients was significantly
higher than that in healthy controls [OR = 0.043(0.021–
Table 1 Demographic and clinical data of COPD and control
subjects.
S. no. Characteristics Patients Controls
1 Total (N = 150) (N= 200)
2 Gender Males 142(94.66) 172(86.0)
Females 08(5.33) 28(14.0)
3 Median age (years) >35 128(85.33) 132(66.0)
635 22(14.66) 68(34.0)
5 Smoking Smokers 138(92.0) 46(25.55)
Non-smokers 12(8.0) 154(77.0)
6 Alcoholism Alcoholics 135(90.0) 78(39.0)
Non-alcoholics 15(10.0) 122(61.0)
Values in parentheses represent percentages N (%) compared to
controls.
Association of ADAM33 gene S1 and S2 transmembrane domain polymorphisms 3210.088), p-value < 0.001*] conferring ‘G’ allele as a predispos-
ing factor for the disease respectively. As per International
HAP Map consortium the present study revealed 28.55%,
which could be due to the ethnic variation within different
regions of South-Indian population. The ADAM33 gene
frequency in COPD patients was not found to be in Hardy–
Weinberg equilibrium at 55% level of significance. The gene
frequency of control subjects was in Hardy–Weinberg
equilibrium at 5% level of significance.
4. Discussion
COPD is a progressive airflow limitation disease due to
obstructive bronchitis and emphysema and permanent
destruction of alveoli resulting in pulmonary failure. To
demonstrate the evidence for the association of genetic varia-Table 2 Frequency distribution of genotypes and of ADAM33 S1 (A
frequencies was found to be high when compared to controls and p<
in heterozygous or homozygous form is conferring for the disease, wh
present study shows a significant association of G allele (p< 0.001*)
patients.
Genotype Controls (200) Patients (1











A allele 257 (64.25) 126 (42.0)
G allele 143 (35.50) 174(58.0)
There is a statistical difference in the distribution of genotypic and allelic
with different models.
* p< 0.05.tions in the disease, two transmembrane domain SNPs of
ADAM33 S1 and S2 were genotyped and analysed in South-
Indian population by means of a case–control approach. How-
ever, from the data, it is observed that a significant distributive
difference of the tested polymorphisms between COPD
individuals with age and sex matched healthy controls is in
accordance with the disease and its progression.
ADAM proteins are Zn+2-dependent metalloproteinases
with various biological functions, encompassing mainly signal
transduction. Van Eerdewegh et al. (Nature 2002) [15] have
identified ADAM33 as a susceptibility gene for asthma and
demonstrated that ADAM33 is expressed in airway smooth
muscle cells and lung fibroblasts. It may play a possible role
in airway remodelling because of its high expression in epithe-
lium, myofibroblasts or fibroblasts and airway smooth muscle
cells (ASMCs) [37]. Because higher expression of ADAM33 is
found in the fibroblast and smooth muscle cells of the lung,
over or under expression of ADAM33 gene may result in alter-
ations in airway remodelling and repair processes [35]. In con-
sideration of these outcomes, the present study concentrated
on the polymorphisms in ADAM33 gene and their role in
COPD and its progression. However, in opposition to the
other population results, our data suggest that the polymor-
phisms studied have an impact on COPD and its progression.
This could be due to difference in the genetic background and
ethnic variation.
SNPs located in functional domain of the ADAM33 gene
contributed to transcription and expression of ADAM33
mRNA and proteins [39]. These expressed proteins finally
influence the function of ADAM33 in the pathogenesis of
AHR. S1 and S2 are transmembrane polymorphisms located
in exon19 encoding the transmembrane domain, are predicted
to influence anchoring ADAM33 proteins to the cell
membrane. S2 encodes the synonymous exon (Gly717Gly)/G) genotypes with risk of COPD: The AG and GG genotype
0.001* in co-dominant and dominant models indicating ‘G’ allele
ereas in recessive model p-value (p= 0.085) is not significant. The
of ADAM33 S1 (A/G) transdomain polymorphism with COPD










frequencies between the patient and control groups when compared
Table 3 Frequency distribution of genotypes and of ADAM33 S2 (C/G) genotypes with risk of COPD: The CG and GG genotype
frequencies was found to be high when compared to controls and p< 0.05 in co-dominant and dominant models indicating ‘G’ allele in
heterozygous or homozygous form is conferring for the disease, whereas in recessive model p-value (p= 0.244) is not significant. The
present study shows a significant association of G allele (p< 0.001*) of ADAM33 S2 (C/G) transdomain polymorphism with COPD
patients. The present study depicts both the ADAM33 S1 and S2 transmembrane domain polymorphisms show significant association
for the disease in the studied ethnic group.
Genotype Controls (200) Patients (150) OR (95% CI) p-Value
N (%) N (%)
CC 124(62.0) 10(6.67) 1-Reference
CG 32(16.0) 98(65.34) 0.026(0.012–0.056) <0.001*
GG 44(22.0) 42(28.0) 0.084(0.039–0.182) <0.001*
Dominant
CC 124(62.0) 10(6.67) 1-Reference
CG+GG 76(38.0) 140(93.33) 0.043(0.021–0.088) <0.001*
Recessive
CC+ CG 156(78.0) 108(72.0) 1-Reference
GG 44(22.0) 42(28.0) 0.725(0.449–1.180) 0.244
Allele frequency
C allele 280(70.0) 118(39.34) 1-Reference
G allele 120(30.0) 182(60.67) 0.277(0.202–0.380) <0.001*
There is a statistical difference in the distribution of genotypic and allelic frequencies between the patient and control groups when compared
with different models.
* p< 0.05.
322 K. Vijaya Laxmi et al.which does not change amino acid sequence or missense, but
may alter the mRNA folding, mRNA stability and translation
process [41]. Further expression studies are warranted to reveal
the influence of S2 variation to ADAM33 function. S1 SNP
was associated with both excessive FEV1 decline in the general
population and development of COPD. The S1 polymorphism
causes an amino acid change (valine to isoleucine), but it is
unknown whether this also modifies the structure of the pro-
tein [40]. Further, the ADAM33 protein may not be anchored
correctly in the membrane and therefore may not be able to
exert its function. The intracellular domain of ADAM33 is rel-
atively short in comparison with its nearest homologues and is
rich in prolines and has a putative SH3 binding site
(PsWPLDP) affecting the function [35]. There is an association
between ADAM33 and the severity of AHR in COPD. It is an
important predictor in association with accelerated FEV1
decline for COPD mortality. The exact pathophysiology
underlying AHR in the disease is unclear, but it is thought
to result from an inflammatory process in the airways in addi-
tion to geometric changes owing to airway remodelling [41]. It
is possible that ADAM33 has a role in both these processes
thereby contributing to the severity of AHR and COPD and
its progression.
5. Conclusion
In conclusion, our study is the first to reveal a significant
genetic association of ADAM33 S1-A/G and S2-C/G poly-
morphic variants in the pathophysiology of COPD in the stud-
ied ethnic group.
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